Analysis of the relationship between muscle sympathetic nerve activity and cardiac 123I-metaiodobenzylguanidine uptake in patients with Parkinson's disease

Movement Disorders

Volumn 20, Issue 11, 2005, Pages 1419-1424

  Shindo, Kazumasa ^a   Kaneko, Eri ^a   Watanabe, Harue ^a   Sugimoto, Tetsuhiko ^a   Ohta, Emiko ^a   Ohashi, Kenji ^a   Nagasaka, Takamura ^a   Shiozawa, Zenji ^a  

^a YAMANASHI PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

Cardiac 123I metaiodobenzylguanidine uptake; Functional change; Muscle sympathetic nerve activity; Parkinson's disease; Sympathetic nerve ending

Indexed keywords

(3 IODOBENZYL)GUANIDINE; AMANTADINE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; IODINE 123; PERGOLIDE; TRIHEXYPHENIDYL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PERONEUS NERVE; PREDICTION; PRIORITY JOURNAL; SCINTIGRAPHY; SYMPATHETIC NERVE; SYMPATHETIC TONE;

3-IODOBENZYLGUANIDINE; AGED; AGED, 80 AND OVER; DISABILITY EVALUATION; FEMALE; HEART; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PARKINSON DISEASE; SYMPATHETIC NERVOUS SYSTEM;

EID: 30444442693     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.20580     Document Type: Article

References (14)

1. 123I] MIBG separates Parkinson's disease from multiple system atrophy. Neurology 1999;53:1020-1025.
2. 123I]iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst 1994;49:81-84.
3. 123I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;67:189-194.
4. Druschky A, Hilz MJ, Platsch G, et al. Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J Neurol Sci 2000;175:3-12.
5. 123I-metaiodobenzylguanidine (MIBG) uptake in 100 patients with Parkinson's disease: relationship to onset age and disease duration. Auton Nervous Syst 2002;39:377-382 (in Japanese).
6. 123I-MIBG uptake in Parkinson's disease. Acta Neurol Scand 1998;97:303-306.
7. Taki J, Nakajima K, Hwang E-H, et al. Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med 2000;27:566-573.
8. 123I-meta-iodobenzylguanidine (MIBG) uptake in dementia with Lewy bodies: comparison with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001;70:781-783.
9. Orimo S, Ozawa E, Oka T, et al. Different histopathology accounting for a decrease in myocardial MIBG uptake in PD and MSA. Neurology 2001;57:1140-1141.
10. Shindo K, Watanabe H, Tanaka H, et al. Age and duration related changes in muscle sympathetic nerve activity in Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;74:1407-1411.
11. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
12. Shindo K, Tsunoda S, Shiozawa Z. Microneurographic analysis of muscle sympathetic nerve activity in amyotrophic lateral sclerosis. Clin Auton Res 1993;3:131-135.
13. Iriki M, Kozawa E. Factors controlling the regional differentiation of sympathetic outflow-Influence of the chemoreceptor reflex. Brain Res 1975;87:281-291.
14. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 1998;155:60-67.